Key result
Quality of life is an increasingly recognized outcome measure in atrial fibrillation, though few studies have used properly validated tools to assess the impact of antiarrhythmic drug treatment.
Why the study?
Does antiarrhythmic drug treatment improve quality of life in patients with atrial fibrillation?
Population
Patients with atrial fibrillation
Design
Review
Authors
Loading...
Validated QoL tools remain underused in AF antiarrhythmic studies; leaves open whether treatment improves patient-reported outcomes.
Does antiarrhythmic drug treatment improve quality of life in patients with atrial fibrillation?
This review emphasizes the need for properly validated tools to assess quality of life as an outcome measure in patients with atrial fibrillation receiving antiarrhythmic therapy.
Lüderitz et al. (2000) conducted a review in Atrial fibrillation. Antiarrhythmic drugs was evaluated on Quality of life. Quality of life is an increasingly recognized outcome measure in atrial fibrillation, though few studies have used properly validated tools to assess the impact of antiarrhythmic drug treatment.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: